NuCana plc (Nasdaq:NCNA) is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.
NuCana closed its initial public offering of American Depositary Shares on 2 October 2017 raising total gross proceeds of approximately $114 million (before deducting discounts and commissions).
Bristows advised NuCana on the UK aspects of its initial public offering. The members of the corporate team involved on this transaction included:
- Partners, Mark Hawes and Iain Redford
- Of Counsel, David Horner
- Associates, Tom Clarke, Nick Cross and Sam Munday